What the FDA labels say about taking them together
Elosulfase alfa and epinephrine
Elosulfase alfa's FDA label of October 30, 2025 names epinephrine in its boxed warning section; the epinephrine labels PlainMeds reads (4) do not name elosulfase alfa. The elosulfase alfa label: “… and immediately initiate appropriate medical treatment, including use of epinephrine. Patients with acute respiratory illness may be at risk of serious acute exacerbation of their respiratory compromise due to …”
Check it at the source: the elosulfase alfa FDA label on DailyMed (effective October 30, 2025, BioMarin Pharmaceutical Inc.); the epinephrine FDA label on DailyMed (effective July 13, 2026, A-S Medication Solutions).
What does the elosulfase alfa label say about epinephrine?
Elosulfase alfa label, boxed warningAnaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. ( 5.1 ) Initiate VIMIZIM in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. ( 5.1 ) If a severe hypersensitivity reaction (anaphylaxis) occurs, discontinue VIMIZIM and immediately initiate appropriate medical treatment, including use of epinephrine. ( 5.1 ) Patients with acute respiratory illness may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions, and require additional monitoring
Elosulfase alfa label, warnings and precautionsIf a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue VIMIZIM and immediately initiate appropriate medical treatment, including use of epinephrine.
Source: FDA drug label (VIMIZIM), BioMarin Pharmaceutical Inc., effective October 30, 2025 (SPL set 0caa2565-12b2-0ad0-1f9a-273e81c3d4cc), via openFDA; the full label on DailyMed
What does the epinephrine label say about elosulfase alfa?
Epinephrine's label (effective July 13, 2026) and its 3 other brand-application labels do not name elosulfase alfa in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Epinephrine), A-S Medication Solutions, effective July 13, 2026 (SPL set 6e811e28-0199-4df7-a916-5940c632401d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Elosulfase alfa | Epinephrine | |
|---|---|---|
| Labeled for | n/a | Asthma |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | $123.51 per unit 0.15 mg auto-injct |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once